6505--Ticagrelor Tablets

The VA is soliciting offers for the supply of Ticagrelor tablets (60 mg and 90 mg strengths) in various bottle configurations to support the VA, DoD, IHS, BOP, and other federal health‑care entities through the Pharmaceutical Prime Vendor (PPV) programs. One award will be made for either Group I (multiple bottle sizes) or Group II (single 60‑tablet bottles). Offers must include pricing for the base year and four one‑year options, incorporate a 0.5 % cost‑recovery fee, and provide unique 11‑digit NDC numbers. The contract will be a firm‑fixed‑price, indefinite‑delivery/requirements (IDIQ) vehicle with a base year plus four optional years, totaling up to five years. The contractor must maintain FDA cGMP compliance, secure a Letter of Commitment from manufacturers (if not the manufacturer), and establish business‑to‑business agreements with the PPV distributors. • Solicitation ID: 36E79726R0028 (issued 08‑26‑2026) • Offer deadline: 09‑17‑2026 2:30 PM CDT (extended) • Product: Ticagrelor 60 mg & 90 mg tablets, packaged in 60‑tablet, 500‑tablet, or 1,000‑tablet bottles • Quantity: ~21,137 bottles (60 tablet) + additional bulk bottles per year (see schedule) • Contract type: Firm‑fixed‑price IDIQ, base year + four 1‑year options (max 5 years) • Evaluation: Lowest‑priced technically acceptable offer; one award for either Group I or Group II • Required documentation: NDC numbers, FDA approval evidence, Letter of Commitment (if distributor), subcontracting plan (if > $900 k) • Delivery: FOB destination to PPV distribution centers nationwide • Small‑business size standard: 1,300 employees (500 emp. for non‑manufacturer offers) • Contact: Kenneth Lay, Contract Specialist ([email protected], (708) 786‑4879)